CG Oncology Inc. (NASDAQ: CGON)
$37.66
+1.0000 ( +2.73% ) 487.1K
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Market Data
Open
$37.66
Previous close
$36.66
Volume
487.1K
Market cap
$2.51B
Day range
$36.00 - $38.12
52 week range
$25.77 - $50.23
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
3 | Insider transactions | 2 | Jan 24, 2024 |
3 | Insider transactions | 2 | Jan 24, 2024 |
3 | Insider transactions | 2 | Jan 24, 2024 |
3 | Insider transactions | 2 | Jan 24, 2024 |
3 | Insider transactions | 2 | Jan 24, 2024 |
3 | Insider transactions | 2 | Jan 24, 2024 |